Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:00 PM PST. CEO Sarah Boyce and CSO Art Levin will engage in a virtual fireside chat. A live webcast will be available on the company’s website, with a replay archived for 90 days. Avidity is pioneering Antibody Oligonucleotide Conjugates (AOCs^™) to treat serious diseases, including myotonic dystrophy type 1. For more details, visit www.aviditybiosciences.com.

LA JOLLA, Calif., Feb. 17, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs^™), today announced that Sarah Boyce, President and Chief Executive Officer, and Art Levin, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24^th, 2021 at 2:00pm PST. The conference is being held in a virtual format.

A live webcast of the virtual fireside chat will be available on the Company's website at www.aviditybiosciences.com in the Investors section. A replay of the fireside chat will be archived on the site for 90 days.

About Avidity Biosciences
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead

product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.

Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn.

Contacts:

Company:

Mike MacLean
(858) 401-7900
mikemaclean@aviditybio.com          

Media and Investors:

Cherise Adkins
Spectrum Science
(202) 587-2507
cadkins@spectrumscience.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/avidity-biosciences-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301229158.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences participating in the SVB Leerink Global Healthcare Conference?

Avidity Biosciences will participate in the SVB Leerink Global Healthcare Conference on February 24, 2021.

Who from Avidity Biosciences will be speaking at the conference?

CEO Sarah Boyce and CSO Art Levin will be speaking at the conference.

How can I watch the Avidity Biosciences presentation at the conference?

The presentation will be available via a live webcast on Avidity Biosciences' website.

What is the main focus of Avidity Biosciences?

Avidity Biosciences focuses on developing Antibody Oligonucleotide Conjugates to treat serious diseases.

What is Avidity's lead product candidate?

Avidity's lead product candidate is AOC 1001, aimed at treating myotonic dystrophy type 1.